, , , ,
Int J Dev Neurosci 10(4):321329 Bianchetti A, Rozzini R, Trabucchi M (2003) Effects of acetyl-L-carnitine in Alzheimers disease patients unresponsive to acetylcholinesterase inhibitors
Caballero-Garca A, Pascual-Fernndez J, Noriega-Gonzlez DC, Bello HJ, Pons-Biescas A, Roche E, et al
To address the gastrointestinal side effects associated with semaglutide medications while supporting lean mass preservation, nutritionally designed meal replacements containing whey protein and prebiotic fiber may be considered
Reducing TMAO levels may mitigate inflammation, oxidative stress, endothelial dysfunction, and renal abnormalities, and improving patient outcomes
Another crucial target involved in metabolic diseases and cognitive impairment is the mammalian target of rapamycin (mTOR)